Hanmi Pharmaceutical Company Limited: Hypertension trials

The registry lists 26 Hypertension studies with Hanmi Pharmaceutical Company Limited as lead sponsor. 2 are open to participants now and 1 have results posted.

Phase 1 1Phase 2 3Phase 3 17Phase 4 2No phase 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Effectiveness and Safety of Sequential Triple Combination Therapy (Amlodipine/Losartan/Chlorthalidone) in Korean Patients With HypertensionRecruitingNCT07784296
• A Study to Evaluate Efficacy and Safety of HCP1803-4 in Patients With Essential HypertensionNot yet recruitingNCT07660796Phase 3
• Pharmacokinetic Interaction Between HGP0904, HGP0608 and HGP1405CompletedNCT02387554Phase 1Results posted
• A Study to Evaluate Efficacy and Safety of HCP1803 Compared to RLD2001-1 in Patients with Essential HypertensionCompletedNCT06438172Phase 3
• A Study to Evaluate Efficacy and Safety of HGP2304 in Essential Hypertension PatientsCompletedNCT06174766Phase 3
• An Observational Study to Evaluate Effectiveness and Safety of Amosartan Plus TabletCompletedNCT05462535
• A Study to Evaluate the Efficacy and Safety of HCP2102 in Essential Hypertension PatientsCompletedNCT05450601Phase 3
• An Observational Study to Evaluate Effectiveness and Safety of Amosartan Q TabletCompletedNCT05450575
• A Study to Evaluate Efficacy and Safety of HCP1803 in Patients With Essential HypertensionCompletedNCT05362110Phase 3
• Clinical Efficacy and Safety Evaluation of HCP1904-3 in Essential Hypertension PatientsCompletedNCT05199129Phase 3
• A Phase 2 Study to Explore the Dose of HCP1803 in Patients With Essential HypertensionCompletedNCT04959305Phase 2
• Clinical Efficacy and Safety Evaluation of HCP1904-2 in Essential Hypertension PatientsCompletedNCT04830449Phase 3
• Clinical Efficacy and Safety Evaluation of HCP1904-1 in Essential Hypertension PatientsCompletedNCT04820907Phase 3
• A Phase 3 Study to Compare the Efficacy and Safety of Co-administered HGP0608, HGP0904 and HCP1306 Versus HCP1701 in Patients With Hypertension and DyslipidemiaCompletedNCT04074551Phase 3
• A Phase 2 Study to Assess Dose-response Relationship of HCP1803 in Patients With Essential HypertensionCompletedNCT03897868Phase 2
• Study to Evaluate the Effect on Improvement of LVH by the Control of BP in Hypertension Patients With AV DiseaseCompletedNCT03666351Phase 4
• A Study to Evaluate Efficacy and Safety of HCP1401 for Stage 2 Hypertension Patients Not Controlled by HCP0605CompletedNCT02916602Phase 3
• Clinical Efficacy and Safety Evaluation of Co-administered HGP0904, HGP0608 and HGP0816 in Patients With Hypertension and DyslipidemiaCompletedNCT02899455Phase 3
• Trial to Evaluate the Efficacy and Safety of HCP1302CompletedNCT02587988Phase 3
• Safety and Efficacy Study of HGP1207 in Patients With Pulmonary HypertensionStatus unknownNCT01913847Phase 3
• The Efficacy and Safety Study of Anti-hypertension Combination Drug in Patients Uncontrolled With Monotherapy.CompletedNCT01828359Phase 4
• Efficacy and Safety of Irbesartan and Atorvastatin in Hypertension and HyperlipidemiaCompletedNCT01442987Phase 3
• Efficacy/Safety of Amlodipine Plus Losartan Versus Amlodipine in Patients With Stage 2 HypertensionCompletedNCT01127217Phase 3
• Efficacy and Safety of Amlodipine and Losartan in Patients With Essential HypertensionCompletedNCT00942344Phase 2
• Efficacy/Safety of Amlodipine Plus Losartan Versus Losartan in Patients With Essential HypertensionCompletedNCT00940680Phase 3
• Efficacy/Safety of Amlodipine Plus Losartan Versus Amlodipine in Patients With Essential HypertensionCompletedNCT00940667Phase 3